EyePoint Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2021-06-22

Reporting Person: Godshall Douglas Evan (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-22	Common Stock	M	2500.00	$0.00	Acquired	8016.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-22	Restricted Stock Units	$0.00	M	2500.00	Acquired		Common Stock (2500.00)	Direct
2021-06-22	Stock Option (Right to Buy)	$13.13	A	11000.00	Acquired	2023-06-22	Common Stock (11000.00)	Direct

Footnotes

F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021.

F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.

F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.